Loading stock data…
$11.97-0.24 (-2.00%)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.
MediWound Ltd. in the Healthcare sector is trading at $12.19 with a market capitalization of $175M. Wall Street consensus targets $30.67 (6 analysts), implying a +151.6% move over the next 12 months. The stock is currently near its 52-week low of $12.17, remaining 21.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.09M↑ | $1.48M↓ | $1.87M↓ | $5.43M↓ | $5.71M |
| Gross Profit | $337,000↑ | $323,000↑ | $278,000↓ | $896,000↓ | $1.34M |
| Operating Income | -$9.46M↓ | -$7.98M↓ | -$7.81M↓ | -$6.53M↓ | -$5.72M |
| Net Income | -$7.39M↓ | -$2.95M↑ | -$7.18M↓ | -$2.65M↑ | -$13.32M |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The compan...